p53 in prostate cancer: frequent expressed transition mutations.
about
Treatment options in androgen-independent prostate cancer.Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer.Post genome-wide association studies functional characterization of prostate cancer risk loci.Use of a yeast assay to detect functional alterations in p53 in prostate cancer: review and future directions.Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancerA mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses.P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancersOncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancerMolecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer.Heterogeneity in intratumor distribution of p53 mutations in human prostate cancerUbiquitin C-terminal hydrolase l1 in tumorigenesisInitiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression.Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective.Chunghyuldan activates NOS mRNA expression and suppresses VCAM-1 mRNA expression in human endothelial cells.Effect of Uwhangchungsimwon on expression of nitric oxide synthase and vascular cell adhesion molecule-1 in human endothelial cells.Effects of uwhangchungsimwon on cell viability, proliferation, and gene expression of human neuronal cell line IMR32.Inhibition of human smooth muscle cell proliferation by gamigeonsim-tang through the transcriptional regulation of cell cycle-controlling genes.Id4 dependent acetylation restores mutant-p53 transcriptional activity.miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes.Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery.Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications.Alterations of the retinoblastoma gene in human prostate adenocarcinoma.Diagnostic and prognostic markers for human prostate cancer.Genomic analysis of cancer tissue reveals that somatic mutations commonly occur in a specific motif.Biomarkers for prostate cancer: who will benefit from local treatment, who harbors occult systemic disease and who needs treatment at all?p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.Complex functions of mutant p53 alleles from human prostate cancer.Gene gravity-like algorithm for disease gene prediction based on phenotype-specific network.Abnormal expression of MDM2 in prostate carcinoma.
P2860
Q33539954-65476675-D26E-496D-9126-CF1153C55984Q33687282-2FDA4CCE-A49A-4C22-9374-CCC938762542Q33702079-253F5024-13C1-46D7-AF15-AB1FBDE3C946Q33729053-866F9203-54BB-4A7D-868C-9B9FAADD65A9Q33808309-539F7569-4C6B-436B-9738-0AEC23074188Q33862890-FFC8BCC5-8C9E-4D36-A1D5-A80A4CCBF78FQ33936343-37BCB197-ADD9-4185-A651-F73DD6891C04Q34557323-38D9E583-F652-4462-A244-179C575CB37BQ34636497-A354D6C3-F164-4DCE-9879-6BE662A7839DQ34667906-F3AFB82E-A724-4C2B-B4E0-FC154E1FCD9DQ35764421-B8131853-AB47-4AF8-93D9-645A48835959Q35796293-54FFD6B9-4AF5-4504-8A3C-AE664C0F4E9FQ36091119-3BD40755-280F-4C69-B66A-94C9DCD84221Q36359259-523697AC-37D9-4157-892B-1C33AC2D3DD6Q38060845-AFBBB077-0F09-4E81-9F25-2B33EBEF3102Q38511256-30B7E389-2506-4778-B43A-E882CF95493EQ38519676-CFAD9942-B23D-47B6-9AFB-08B2A6DA0A53Q38523579-4B690EDD-6D9D-424A-A998-027E31CB4254Q38526416-C5E0100A-E60B-425A-84EC-2D61ECCEBB3BQ39044368-48B6E2A5-C0DE-4E3C-8219-BE8C10D0ECFBQ39649207-7ECE3742-9CB4-4748-8E45-08930C83C80DQ40872928-90A5AC8B-568B-40CE-86D9-CF9264930A7CQ41130442-EABB5114-3A52-429C-9CE0-85D50AE5CFE1Q41231236-83E23478-2A97-4905-9C84-9A3745F82446Q41495930-5442A7CB-2DC6-42C7-92A1-073299D5366FQ41812715-CD65B339-71EF-4B11-95AB-C44934C51AD1Q45289825-1FE57415-E56C-4C8B-8892-870CBA7922B5Q46766367-39DA2DAC-8C47-45A4-84EA-4018AD7A315EQ46864790-EF52A8E2-B87F-4D2C-9DA8-679A7114E921Q47115723-0C18D3B9-5D78-4EEB-9A74-DF8B7B3894B0Q53398985-93EE4BFA-EEE2-4742-B470-A230C0FA0207
P2860
p53 in prostate cancer: frequent expressed transition mutations.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
p53 in prostate cancer: frequent expressed transition mutations.
@ast
p53 in prostate cancer: frequent expressed transition mutations.
@en
type
label
p53 in prostate cancer: frequent expressed transition mutations.
@ast
p53 in prostate cancer: frequent expressed transition mutations.
@en
prefLabel
p53 in prostate cancer: frequent expressed transition mutations.
@ast
p53 in prostate cancer: frequent expressed transition mutations.
@en
P2093
P356
P1476
p53 in prostate cancer: frequent expressed transition mutations.
@en
P2093
P304
P356
10.1093/JNCI/86.12.926
P407
P577
1994-06-01T00:00:00Z